Dyadic International, Inc. Announces Proposed Public Offering of Common Stock

Core Viewpoint - Dyadic International, Inc. has initiated an underwritten public offering of common stock to raise funds for working capital and general corporate purposes, including product development and marketing efforts [1][2]. Group 1: Offering Details - The public offering is subject to market conditions, and there is no guarantee regarding its completion or the specific terms of the offering [1]. - Craig-Hallum Capital Group LLC is the sole managing underwriter for this offering [2]. - The offering is being conducted under an effective shelf registration statement filed with the SEC, with a preliminary prospectus supplement to be filed [3]. Group 2: Company Overview - Dyadic is a global biotechnology company that specializes in the scalable production of precision-engineered functional input proteins for various applications in life sciences, food and nutrition, and industrial biotechnology [1][5]. - The company utilizes proprietary gene expression platforms, specifically its C1 and Dapibus™ systems, to produce high-quality recombinant proteins [5].